Edgewise Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer Russell Alan J unloaded Company’s shares for reported $25520.0 on May 02 ’25. In the deal valued at $16.45 per share,1,551 shares were sold. As a result of this transaction, Russell Alan J now holds 18,521 shares worth roughly $0.27 million.
Then, MOORE JOHN R sold 1,930 shares, generating $31,757 in total proceeds. Upon selling the shares at $16.45, the General Counsel now owns 6,531 shares.
Before that, KOCH KEVIN sold 4,276 shares. Edgewise Therapeutics Inc shares valued at $70,358 were divested by the President and CEO at a price of $16.45 per share. As a result of the transaction, KOCH KEVIN now holds 20,619 shares, worth roughly $0.3 million.
Guggenheim initiated its Edgewise Therapeutics Inc [EWTX] rating to a Buy in a research note published on April 30, 2025; the price target was $41. A number of analysts have revised their coverage, including Scotiabank’s analysts, who decreased its forecast for the stock in early April from “a Sector outperform” to “a Sector perform”. Scotiabank began covering EWTX with “Sector outperform” recommendation on March 07, 2025. Stifel started covering the stock on January 22, 2025. It rated EWTX as “a Hold”.
Price Performance Review of EWTX
On Monday, Edgewise Therapeutics Inc [NASDAQ:EWTX] saw its stock jump 0.07% to $14.79. Over the last five days, the stock has lost -0.20%. Edgewise Therapeutics Inc shares have fallen nearly -44.61% since the year began. Nevertheless, the stocks have fallen -16.35% over the past one year.
How much short interest is there in Edgewise Therapeutics Inc?
A steep rise in short interest was recorded in Edgewise Therapeutics Inc stocks on 2025-04-30, growing by 2.87 million shares to a total of 13.26 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 10.39 million shares. There was a rise of 21.65%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 22, 2024 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating along with a $45 price target.
